Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FDA approves new fast, convenient treatment for advanced follicular lymphoma.
The FDA has approved Genentech’s Lunsumio VELO for treating adults with relapsed or refractory follicular lymphoma after two or more prior therapies.
The subcutaneous injection, given in one minute, replaces a previous IV infusion that took up to four hours.
Clinical data showed a 75% objective response rate and 59% complete response rate.
The new method offers faster treatment and improved patient convenience.
5 Articles
FDA aprueba un nuevo tratamiento rápido y conveniente para el linfoma folicular avanzado.